Three ongoing intraperitoneal chemotherapy trials in ovarian cancer
نویسنده
چکیده
منابع مشابه
Hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer.
Ovarian cancer remains the fourth leading cause of cancer death in women in France. It is all too often diagnosed at an advanced stage with peritoneal carcinomatosis (PC), but remains confined to the peritoneal cavity throughout much of its natural history. Because of cellular selection pressure over time, most tumor recurrences eventually develop resistance to systemic platinum. Options for sa...
متن کاملUpdate of randomized trials in first-line treatment.
Advanced-stage epithelial ovarian cancer remains a highly lethal malignancy, in spite of effective cytoreductive surgery and primary chemotherapy. Randomized phase III trials have provided the most consistent platform for the evaluation of new treatment interventions. Recently completed and ongoing international phase III studies in the primary disease setting, summarized and analyzed in the pr...
متن کامل[Intraperitoneal chemotherapy for ovarian cancer: a complex strategy but what an exciting avenue!].
After more than 20 years of investigation, there are now three (3) major North American phase III trials showing positive results (GOG-172, SWOG-9619, GOG-114/SWOG-9227). Chaired by Dr. Deborah Armstrong, the most recent study, GOG-172, observed an improvement in survival for those women treated with intraperitoneal chemotherapy as adjuvant treatment following optimal cytoreduction surgery for ...
متن کاملIntraperitoneal chemotherapy in ovarian cancer: a review of tolerance and efficacy
PURPOSE TO REVIEW THE TWO MAIN APPROACHES OF INTRAPERITONEAL (IP) CHEMOTHERAPY DELIVERY IN OVARIAN CANCER: postoperative adjuvant IP chemotherapy after cytoreductive surgery (CRS) and intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC). METHODS A literature search was conducted to identify studies that employed postoperative adjuvant IP chemotherapy after CRS or combined CRS and ...
متن کاملCONSOLIDATION TREATMENT WITH INTRAPERITONEAL CISPLATIN IN EPITHELIAL OVARIAN CANCER FOLLOWING NEGATIVE SURGICAL ASSESSMENT
Objective: The goal of this study is to evaluate the efficacy of intraperitoneal (JP) cisplatin as consolidation treatment, in epithelial ovarian cancer patients with pathologically negative surgical reassessment, following first-line platinum-based chemotherapy. Methods: This study included 22 patients with FIGO stage (IIc- IV) epithelial ovarian cancer (EOC) which had no evidence of disea...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 23 شماره
صفحات -
تاریخ انتشار 2012